– GERMANY, Jena – InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced the appointment of Tony Gibney to its Board as a Non-Executive Director.
Mr. Gibney is a highly experienced life sciences-focused biotech executive and former investment banker who has executed over 150 financings and M&A advisory transactions for US and European clients.
“We are excited that Tony is joining the InflaRx board. He has tremendous experience in the biotech industry, having served as a senior executive in the financial sector and different companies,” said CEO and Founder, Prof. Niels Riedemann. “Our entire team feels fortunate about his commitment and willingness to help InflaRx with its endeavors. We are also very happy to announce the re-election of Lina Ma and Mark Kübler as board members. Both have contributed to InflaRx for many years and were instrumental in our successful IPO in 2017.”
About Tony Gibney
Tony Gibney is currently the CFO and CBO at FogPharma, overseeing and driving the business development, strategy, and finance functions of the company. Tony served as the EVP and CBO of Achillion Pharmaceuticals, Inc. from 2018 to 2020, where he was responsible for corporate and portfolio strategy, business development, and corporate communications and led the successful sale of Achillion to Alexion in 2020. Before Achillion, Tony was a life sciences-focused investment banker for 24 years. From 2009 through 2018, he served as a managing director and co-head of the biotechnology investment banking team for Leerink Partners LLC. From 1999 to 2009, he was a managing director in the Life Sciences team at Merrill Lynch Inc. and executed a variety of significant financing and M&A transactions while leading the firm’s East Coast biotechnology effort. Tony began his investment banking career in the Healthcare Group at Lehman Brothers in 1993.
Tony Gibney said: “I am gratified to have been offered the opportunity to return to the Board of InflaRx, especially at such an important time in the Company’s evolution as the leader in complement C5a inhibition. I hope that my experience in the complement arena, strategy, and finance can provide incremental support to our strong Board of Directors and deep leadership team at InflaRx, as we look forward to multiple value-driving clinical readouts in indications with critical unmet needs and devastating morbidities. I am convinced that InflaRx’s unique pathway can play an impactful role for patients.”
He graduated from Yale University in 1993 with a B.A. in History and Economics.
About InflaRx N.V.:
InflaRx is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. Complement C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA.
For more information: https://www.inflarx.de/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.